Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen reports developments as a clinical-stage biotechnology company developing Wnt-based targeted therapeutics for sight-threatening ophthalmic diseases. Company updates center on its ophthalmology pipeline, including SZN-8141 and SZN-8143 in retinal diseases, antibody-engineering work, financial results, collaboration and license revenue, and research milestones tied to Boehringer Ingelheim.
Recurring announcements also cover healthcare investor conference presentations, Nasdaq inducement equity grants under the 2025 Equity Inducement Plan, and corporate governance or leadership matters that affect the company's public-company reporting profile.
Surrozen (Nasdaq: SRZN) announced that company management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026. The presentation will be a fireside chat at 11:30 AM Eastern Time / 8:30 AM Pacific Time.
A live audio webcast will be available via the Investors section of Surrozen’s website, with a replay archived on surrozen.com for at least 30 days.
Surrozen (Nasdaq: SRZN) reported Q1 2026 results and a business update. The company had $106.9 million in cash and cash equivalents as of March 31, 2026, and recognized $5.0 million collaboration revenue from a Boehringer Ingelheim milestone. Surrozen remains on track to submit an IND for SZN-8141 in H2 2026. R&D expenses were $9.3 million and G&A expenses were $6.1 million for the quarter. Net loss was $127.5 million or $11.65 per share, driven largely by non-cash changes in fair value of tranche and warrant liabilities.
Surrozen (Nasdaq: SRZN) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) dated April 24, 2026. The company granted a non-statutory stock option for 2,020 shares to a newly hired non-executive employee under the 2025 Equity Inducement Plan.
The option exercise price is $28.14 per share (Nasdaq closing price on April 24, 2026). The option vests over four years: 25% at the one-year anniversary and the remainder ratably each month over 36 months, subject to continued service.
Surrozen (Nasdaq: SRZN) reported fourth-quarter and full-year 2025 results and a business update on March 23, 2026. Key items: planned IND submission for SZN-8141 in H2 2026, a $5.0M milestone payment from Boehringer Ingelheim for SZN-413, and presentations at ARVO 2026.
Financials: cash and cash equivalents $89.2M as of Dec 31, 2025; FY2025 net loss $242.0M ($32.37/share); R&D expenses $29.4M; continued pipeline and leadership hires to support ophthalmology strategy.
Surrozen (Nasdaq: SRZN) will present at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026 with a fireside chat at 1:10 PM ET / 10:10 AM PT. Interested parties can listen via a live audio webcast.
A replay will be archived on the company website for at least 30 days following the event.
Surrozen (Nasdaq: SRZN) granted a non-statutory stock option for 3,070 shares to a newly hired non-executive employee as an inducement under its 2025 Equity Inducement Plan.
The option price is $24.53 per share (Nasdaq close on February 17, 2026) and vests over four years with 25% after one year and monthly vesting thereafter.
Surrozen (Nasdaq: SRZN) will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 1:30 PM ET / 10:30 AM PT. Management will deliver a live presentation and audio webcast.
According to the company, the live audio webcast is available via the Investors section of Surrozen's website and a replay will be archived for at least 30 days.
Surrozen (Nasdaq: SRZN) said company management will present at two healthcare investor conferences in early December 2025: the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025 (fireside discussion at 6:30 AM PT / 9:30 AM ET) and the 8th Annual Evercore Healthcare Conference on December 3, 2025 (fireside chat at 12:25 PM PT / 3:25 PM ET).
Investors can access live audio webcasts and later replays via the Surrozen Investors website at https://investors.surrozen.com/events-presentations/events-calendar or archived at www.surrozen.com.
Surrozen (Nasdaq: SRZN) announced an inducement stock option grant to newly appointed CFO Andrew P. Maleki.
On November 6, 2025 the board approved options covering 50,000 shares under the company’s 2025 Equity Inducement Plan, exercisable at $12.94 per share (Nasdaq closing price on November 12, 2025). The options vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, subject to continuous service.
The awards were granted as an inducement material to acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Surrozen (Nasdaq: SRZN) reported third quarter 2025 results and a business update on Nov 7, 2025. Key clinical and corporate points: the company remains focused on its ophthalmology pipeline with lead candidates SZN-8141 and SZN-8143 and is on track to submit an IND for SZN-8141 in 2026. Leadership: Andrew Maleki joined as CFO; Charles Williams will continue as COO.
Q3 financials: cash $81.3M, collaboration revenue $0 (vs $10.0M in Q3 2024), R&D $7.8M, G&A $4.1M, net loss $71.6M or ($8.36) per share; noncash losses included $40.7M tranche liability and $20.9M other expense.